MedTrace Logo

Drug Response Testing and Repurposing Using Glioblastoma Organoid

NCT06782984 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-01-20

No results posted yet for this study

Summary

The aim of this observational study, based on a prospectively collected cohort, is to evaluate the prognostic value of patient-derived organoids in predicting responses to conventional and repurposing drugs, including temozolomide, in patients with primary or recurrent glioblastoma. The primary question is whether the patient's response to temozolomide is recapitulated in their corresponding patient-derived glioblastoma organoid (GBO). Patient drug responses are evaluated using survival data, while GBO drug responses are assessed through a drug-response testing platform utilizing cell viability assays. Additionally, this platform is used to explore the potential application of various chemotherapeutic agents.

Conditions

Interventions

OTHER

Organoid-based drug sensitivity test

The intervention in this study involves utilizing glioblastoma organoids (GBOs) to perform an organoid-based drug sensitivity test (DST) and retrospectively comparing the results with clinical outcomes. Notably, no interventions will be applied to participants based on GBO-DST results; the study is limited to retrospective analysis. The GBO-DST is conducted by performing a drug response assay with temozolomide to determine the half-maximal inhibitory concentration (IC50), which serves to classify GBOs as TMZ-sensitive or TMZ-resistant. This classification is further validated through GBO cell survival analysis.

Sponsors & Collaborators

  • Korea Advanced Institute of Science and Technology

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    collaborator OTHER

  • Soonchunhyang University Hospital

    collaborator OTHER

  • Dong-A University Hospital

    collaborator OTHER

  • Yeungnam University Hospital

    collaborator OTHER

  • Chungnam National University Hospital

    lead OTHER

Principal Investigators

  • Kyung Hwan Kim, MD, PhD · Department of Neurosurgery, Chungnam National University Hospital

  • Kijoon Yoon, PhD · Korea Advanced Institute of Science and Technology

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-18
Primary Completion
2028-12-31
Completion
2030-12-31

Countries

  • South Korea

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06782984 on ClinicalTrials.gov